Videos

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Smith on PI3K Inhibitors in CLL

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Dr. Tabbara on Treatment for Transplant-Eligible and -Ineligible Patients With Multiple Myeloma

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Dr. Smith on Frontline Treatment Considerations in CLL

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia. 

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

Articles

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

The George Washington Cancer Center

Latest from The George Washington Cancer Center

New content coming soon, please check back later.